MiMedx announces a new study in the Journal of Inflammation supporting its amniotic membrane products' immunomodulatory effects.
Quiver AI Summary
MiMedx Group, Inc. announced the publication of a new study in the Journal of Inflammation that supports the use of its dehydrated human amnion chorion membrane (DHACM) and lyophilized human amnion chorion membrane (LHACM) products. The study, titled “Immunomodulatory Effects of Purion Processed Human Amniotic Membrane Allografts In Vitro,” highlights the immunomodulatory properties of these allografts, which correlate with positive clinical outcomes. CEO Joseph H. Capper emphasized the company's commitment to robust research, noting the importance of high-quality evidence amid evolving local coverage determinations. The findings suggest that DHACM and LHACM can effectively regulate inflammatory responses and promote healing in complex wounds characterized by chronic inflammation. MiMedx continues to lead in the field of healing solutions with a focus on innovation.
Potential Positives
- MiMedx published new peer-reviewed research demonstrating the immunomodulatory properties of its DHACM and LHACM products, reinforcing the scientific basis for its technology.
- The findings support the effectiveness of MiMedx's products in enhancing wound healing, which can improve clinical outcomes for patients with complex wounds.
- This publication adds to MiMedx's extensive library of clinical and scientific research, bolstering its reputation and competitive position in the marketplace.
- The emphasis on high-quality evidence in the market, as highlighted by the pending Local Coverage Determinations (LCDs), aligns positively with MiMedx's ongoing research efforts.
Potential Negatives
- The press release emphasizes the company's need to support its products with scientific evidence, suggesting potential weaknesses in existing data or efficacy.
- There is a reference to "pending Local Coverage Determinations (LCDs)," indicating that the company's products may be subject to increased scrutiny or changes in reimbursement policies.
- The focus on chronic wound treatment implies that the company may still be addressing persistent issues related to these challenging medical conditions.
FAQ
What recent research did MiMedx publish?
MiMedx published a study on immunomodulatory effects of their human amniotic membrane allografts in the Journal of Inflammation.
What are DHACM and LHACM products?
DHACM stands for dehydrated human amnion chorion membrane and LHACM stands for lyophilized human amnion chorion membrane, both of which are MiMedx products.
How do DHACM and LHACM aid in wound healing?
These allografts regulate inflammatory responses and enhance pro-reparative functions, which can help in healing chronic wounds.
What is the significance of the new publication?
The publication adds to MiMedx's research library, emphasizing the importance of high-quality evidence in wound care as outlined by upcoming Local Coverage Determinations.
Where can I access the published study?
The study, titled “Immunomodulatory Effects of Purion Processed Human Amniotic Membrane Allografts In Vitro,” is available online in the Journal of Inflammation.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MDXG Insider Trading Activity
$MDXG insiders have traded $MDXG stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $MDXG stock by insiders over the last 6 months:
- KIMBERLY MAERSK-MOLLER (Chief Commercial Officer) sold 58,300 shares for an estimated $432,329
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MDXG Revenue
$MDXG had revenues of $113.7M in Q3 2025. This is an increase of 35.3% from the same period in the prior year.
You can track MDXG financials on Quiver Quantitative's MDXG stock page.
$MDXG Hedge Fund Activity
We have seen 104 institutional investors add shares of $MDXG stock to their portfolio, and 119 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FIRST LIGHT ASSET MANAGEMENT, LLC added 1,725,458 shares (+89.5%) to their portfolio in Q3 2025, for an estimated $12,043,696
- NANTAHALA CAPITAL MANAGEMENT, LLC added 1,466,566 shares (+inf%) to their portfolio in Q3 2025, for an estimated $10,236,630
- DISCIPLINED GROWTH INVESTORS INC /MN added 1,022,202 shares (+283.0%) to their portfolio in Q3 2025, for an estimated $7,134,969
- HARBOR CAPITAL ADVISORS, INC. removed 833,432 shares (-71.3%) from their portfolio in Q3 2025, for an estimated $5,817,355
- TRIGRAN INVESTMENTS, INC. removed 689,430 shares (-8.2%) from their portfolio in Q3 2025, for an estimated $4,812,221
- ROYCE & ASSOCIATES LP removed 577,703 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $3,529,765
- MILLENNIUM MANAGEMENT LLC removed 534,790 shares (-32.0%) from their portfolio in Q3 2025, for an estimated $3,732,834
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MDXG Analyst Ratings
Wall Street analysts have issued reports on $MDXG in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Mizuho issued a "Outperform" rating on 12/17/2025
- Cantor Fitzgerald issued a "Overweight" rating on 07/31/2025
To track analyst ratings and price targets for $MDXG, check out Quiver Quantitative's $MDXG forecast page.
$MDXG Price Targets
Multiple analysts have issued price targets for $MDXG recently. We have seen 2 analysts offer price targets for $MDXG in the last 6 months, with a median target of $11.0.
Here are some recent targets:
- Anthony Petrone from Mizuho set a target price of $10.0 on 12/17/2025
- Ross Osborn from Cantor Fitzgerald set a target price of $12.0 on 07/31/2025
Full Release
MARIETTA, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the latest addition to its industry-leading body of scientific and clinical evidence supporting the use of its dehydrated human amnion chorion membrane (DHACM) and lyophilized human amnion chorion membrane (LHACM) products, in the Journal of Inflammation . The article, “Immunomodulatory Effects of Purion Processed Human Amniotic Membrane Allografts In Vitro ” can be accessed online here .
“Our team has once again demonstrated MIMEDX’s commitment to generating robust and impactful peer-reviewed research, highlighting the capacity of our technology and the products that are derived from our proprietary tissue processing methodology,” stated Joseph H. Capper, MIMEDX Chief Executive Officer. “In this latest publication, we were pleased to find that our DHACM and LHACM allografts exhibited immunomodulatory properties that correspond with the beneficial outcomes we observe in the clinical setting. This study marks another important contribution to our comprehensive library of clinical and scientific research, which has positioned us favorably in our marketplace, especially considering the renewed emphasis the pending Local Coverage Determinations (LCDs) place on the production of high-quality evidence.”
The study evaluated two configurations of Purion processed placental allografts, DHACM and LHACM, for their ability to regulate key cell types in the inflammatory cascade. The findings illustrate a multifactorial immunomodulatory effect whereby DHACM and LHACM allografts regulate critical functions of inflammatory monocyte and macrophage biology, while enhancing pro-reparative functions including efferocytosis and cell survival. This study is highly relevant, as complex wounds are frequently characterized by persistent inflammation within the wound bed, which contributes to chronicity and poor clinical outcomes; therefore, DHACM and LHACM represent promising interventions to help restore and reset the normal wound-healing cascade.
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit
www.mimedx.com
.
Contact:
Matt Notarianni
Investor Relations
470-304-7291
[email protected]
